Mandate

Vinge Advises Active Biotech on Public Acquisition

April 18, 2008

The biotechnical company Active Biotech, listed on OMX Nordic Exchange in Stockholm will carry out a new share issue valued at SEK 160 million with preferential rights for its shareholders.

Active Biotech is represented by Erik Sjöman joined by Christian Lindhé.  

Related

Vinge advises Main Capital and Björn Lundén in connection with the acquisition of Aprello

Vinge has advised Björn Lundén, a provider of accounting and financial administration software, in connection with the acquisition of Aprello AB (“Aprello”). The strategic acquisition complements Björn Lundén’s growth strategy in the European financial administration software market.
January 30, 2025

Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance

Vinge has advised ABG Sundal Collier in connection with EQL Pharma AB (publ)’s ( “EQL”) inaugural issuance of SEK 350,000,000 senior secured bonds within a framework of up to SEK 700,000.
January 24, 2025

Vinge advises the majority shareholders Altor, Telia Company, Time For Growth and Zenith VC in the divestment of shares in Marshall Group

Vinge advises the majority shareholders Altor, Telia Company, Time For Growth and Zenith VC in connection with the divestment of shares in Marshall Group AB (publ) (”Marshall Group”) to HongShan Group, formerly known as Sequoia China. The Marshall Family will continue as owner in the Marshall Group.
January 24, 2025